vs

Side-by-side financial comparison of Emerson Electric (EMR) and LESAKA TECHNOLOGIES INC (LSAK). Click either name above to swap in a different company.

Emerson Electric is the larger business by last-quarter revenue ($4.6B vs $3.0B, roughly 1.5× LESAKA TECHNOLOGIES INC). Emerson Electric runs the higher net margin — 13.5% vs 0.0%, a 13.5% gap on every dollar of revenue. On growth, Emerson Electric posted the faster year-over-year revenue change (3.0% vs 0.2%). Over the past eight quarters, LESAKA TECHNOLOGIES INC's revenue compounded faster (352.8% CAGR vs -0.6%).

Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

EMR vs LSAK — Head-to-Head

Bigger by revenue
EMR
EMR
1.5× larger
EMR
$4.6B
$3.0B
LSAK
Growing faster (revenue YoY)
EMR
EMR
+2.8% gap
EMR
3.0%
0.2%
LSAK
Higher net margin
EMR
EMR
13.5% more per $
EMR
13.5%
0.0%
LSAK
Faster 2-yr revenue CAGR
LSAK
LSAK
Annualised
LSAK
352.8%
-0.6%
EMR

Income Statement — Q3 FY2026 vs Q1 FY2027

Metric
EMR
EMR
LSAK
LSAK
Revenue
$4.6B
$3.0B
Net Profit
$618.0M
$437.0K
Gross Margin
53.1%
Operating Margin
2.2%
Net Margin
13.5%
0.0%
Revenue YoY
3.0%
0.2%
Net Profit YoY
43.7%
EPS (diluted)
$1.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EMR
EMR
LSAK
LSAK
Q3 26
$3.0B
Q2 26
$4.6B
Q1 26
$4.3B
Q4 25
$4.3B
$178.7M
Q3 25
$4.9B
$171.4M
Q2 25
$4.6B
$168.5M
Q1 25
$4.4B
$161.4M
Q4 24
$4.2B
$176.2M
Net Profit
EMR
EMR
LSAK
LSAK
Q3 26
$437.0K
Q2 26
$618.0M
Q1 26
$606.0M
Q4 25
$605.0M
$3.6M
Q3 25
$637.0M
$-4.3M
Q2 25
$586.0M
$-28.4M
Q1 25
$485.0M
$-22.1M
Q4 24
$585.0M
$-32.5M
Gross Margin
EMR
EMR
LSAK
LSAK
Q3 26
Q2 26
53.1%
Q1 26
53.2%
Q4 25
53.2%
31.4%
Q3 25
51.9%
30.9%
Q2 25
52.6%
28.9%
Q1 25
53.5%
27.5%
Q4 24
53.5%
25.7%
Operating Margin
EMR
EMR
LSAK
LSAK
Q3 26
2.2%
Q2 26
Q1 26
Q4 25
17.8%
1.2%
Q3 25
16.4%
0.2%
Q2 25
16.1%
-16.7%
Q1 25
14.2%
0.4%
Q4 24
18.6%
0.3%
Net Margin
EMR
EMR
LSAK
LSAK
Q3 26
0.0%
Q2 26
13.5%
Q1 26
13.9%
Q4 25
13.9%
2.0%
Q3 25
13.1%
-2.5%
Q2 25
12.9%
-16.9%
Q1 25
10.9%
-13.7%
Q4 24
14.0%
-18.4%
EPS (diluted)
EMR
EMR
LSAK
LSAK
Q3 26
Q2 26
$1.10
Q1 26
$1.07
Q4 25
$1.07
$0.04
Q3 25
$1.12
$-0.05
Q2 25
$1.04
$-0.40
Q1 25
$0.86
$-0.27
Q4 24
$1.02
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EMR
EMR
LSAK
LSAK
Cash + ST InvestmentsLiquidity on hand
$1.8B
$1.5B
Total DebtLower is stronger
$13.4B
$3.2B
Stockholders' EquityBook value
$20.3B
Total Assets
$42.1B
$11.5B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EMR
EMR
LSAK
LSAK
Q3 26
$1.5B
Q2 26
$1.8B
Q1 26
$1.7B
Q4 25
$69.5M
Q3 25
$72.2M
Q2 25
$76.5M
Q1 25
$71.0M
Q4 24
$60.6M
Total Debt
EMR
EMR
LSAK
LSAK
Q3 26
$3.2B
Q2 26
$13.4B
Q1 26
$13.4B
Q4 25
$7.6B
$216.8M
Q3 25
$8.9B
$208.1M
Q2 25
$8.3B
$200.8M
Q1 25
$8.2B
$194.7M
Q4 24
$6.6B
$148.7M
Stockholders' Equity
EMR
EMR
LSAK
LSAK
Q3 26
Q2 26
$20.3B
Q1 26
$20.3B
Q4 25
$20.3B
$180.6M
Q3 25
$20.3B
$170.4M
Q2 25
$19.9B
$161.6M
Q1 25
$19.2B
$185.2M
Q4 24
$20.5B
$193.3M
Total Assets
EMR
EMR
LSAK
LSAK
Q3 26
$11.5B
Q2 26
$42.1B
Q1 26
$41.9B
Q4 25
$41.9B
$704.6M
Q3 25
$42.0B
$652.9M
Q2 25
$42.5B
$653.7M
Q1 25
$42.0B
$649.2M
Q4 24
$42.6B
$640.6M
Debt / Equity
EMR
EMR
LSAK
LSAK
Q3 26
Q2 26
0.66×
Q1 26
0.66×
Q4 25
0.37×
1.20×
Q3 25
0.44×
1.22×
Q2 25
0.42×
1.24×
Q1 25
0.42×
1.05×
Q4 24
0.32×
0.77×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EMR
EMR
LSAK
LSAK
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$694.0M
FCF MarginFCF / Revenue
15.2%
Capex IntensityCapex / Revenue
4.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EMR
EMR
LSAK
LSAK
Q3 26
Q2 26
Q1 26
Q4 25
$699.0M
$-10.9M
Q3 25
$3.1B
$8.9M
Q2 25
$1.1B
$-9.1M
Q1 25
$241.0M
$10.7M
Q4 24
$777.0M
$-9.2M
Free Cash Flow
EMR
EMR
LSAK
LSAK
Q3 26
Q2 26
$694.0M
Q1 26
$602.0M
Q4 25
$602.0M
$-14.8M
Q3 25
$2.7B
$4.9M
Q2 25
$977.0M
$-13.2M
Q1 25
$154.0M
$7.8M
Q4 24
$694.0M
$-15.5M
FCF Margin
EMR
EMR
LSAK
LSAK
Q3 26
Q2 26
15.2%
Q1 26
13.9%
Q4 25
13.9%
-8.3%
Q3 25
54.9%
2.9%
Q2 25
21.5%
-7.8%
Q1 25
3.5%
4.9%
Q4 24
16.6%
-8.8%
Capex Intensity
EMR
EMR
LSAK
LSAK
Q3 26
Q2 26
4.0%
Q1 26
2.2%
Q4 25
2.2%
2.2%
Q3 25
8.9%
2.3%
Q2 25
2.0%
2.4%
Q1 25
2.0%
1.7%
Q4 24
2.0%
3.6%
Cash Conversion
EMR
EMR
LSAK
LSAK
Q3 26
Q2 26
Q1 26
Q4 25
1.16×
-2.99×
Q3 25
4.86×
Q2 25
1.83×
Q1 25
0.50×
Q4 24
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons